MedWatch

Sofinnova raises EUR 472m for life science fund

Now is the time to invest in healthcare, says Sofinnova Partners, as it announces a new fund to back life science startups.

Photo: Antonio Bronic/Reuters/Ritzau Scanpix

The European venture capital firm Sofinnova, which specializes in life sciences and healthcare, has raised its tenth life science fund for startups in Europe, writes the European business media Sifted.

The life science fund has backed some unicorn companies – which is a startup valued at USD 1bn – like Ascendis Pharma, Shockwave and Actelion.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs